Follitropin Beta Articles
S-P fertility treatment achieves equivalence
14 July 2008
Akzo Nobel's 2006 net income increases 20%
26 February 2007
Akzo's income hits 313M euro for 3rd-qtr
23 October 2006
Strong Ph II data for Org 36286
2 October 2006
Akzo 2005 income rises 1.7%, Organon gains
13 February 2006
Organon's Follistim launched in Japan
15 August 2005
Akzo Nobel net up 22% on 6% sales growth
25 July 2005
1st-qtr net doubles for Akzo Nobel
25 April 2005
Akzo Nobel's 4th-qtr and 2004 sales down
14 February 2005
Akzo's 2nd-qtr pharma sales slip further
26 July 2004
FDA OKs Akzo's Follistim AQ
29 March 2004
US FDA requests more data on Organon's Follistim-AQ
14 July 2003
Ferring gets US OK for infertility drug
13 May 2002
Akzo set to break record level profits
29 April 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
Akzo Nobel predicts double-digit pharma growth for 2001
10 October 2001
Strong performance in 2000 for Akzo Nobel as pharma drives growth
26 February 2001
Pharmaceutical sales continue to drive growth at Akzo Nobel
25 October 2000
Pharma sales up 39% at Akzo Nobel
28 July 2000
Ares-Serono 1sr qtr net income leaps 39.2%
28 April 2000
Akzo Nobel net income jumps 30%
26 April 2000
Serono "almost perfect biotech investment"
10 March 2000
Puregon pen approved by EMEA
2 March 2000
Akzo results driven by pharma growth
27 October 1999
Akzo Nobel posts solid results for second qtr
29 July 1999
Puregon Solution approved by EMEA
28 April 1999
Pharmaceuticals "star performer" for Akzo
23 February 1999
Akzo Nobel Pharma Sales Slowdown
30 October 1998
FDA Clears rFSH Products From Serono, Akzo Nobel
9 October 1997
Akzo Nobel Sees Earnings Decline
19 August 1996
First Launch Of Organon's Puregon
22 July 1996
EMEA Approves Three More Products
3 June 1996
Showing 1-41 of 41 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
